secukinumab (Cosentyx) Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.
secukinumab (Cosentyx) Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
secukinumab (Cosentyx) For the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
secukinumab (Cosentyx) treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
secukinumab (Cosentyx) Treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.
February 2024 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, February 12) published advice on five medicines.
June 2015 decisions news release The Scottish Medicines Consortium (SMC) has today published advice accepting four new medicines for use in NHSScotland.
July 2016 decisions news release The Scottish Medicines Consortium (SMC) has today published advice accepting five new medicines for routine use in NHSScotland.
January 2021 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 18 January) published advice accepting five new medicines.
August 2016 decisions news release The SMC has today published advice accepting six new medicines for routine use by NHSScotland.
